{"id":"NCT00022516","sponsor":"ETOP IBCSG Partners Foundation","briefTitle":"Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer","officialTitle":"Low-dose Cytotoxics as \"Anti-angiogenesis Treatment\" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-11","primaryCompletion":"2015-01","completion":"2016-08","firstPosted":"2003-01-27","resultsPosted":"2015-12-11","lastUpdate":"2016-09-16"},"enrollment":1086,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Endoxan","Cytoxan"]},{"type":"DRUG","name":"Methotrexate","otherNames":["Trexall"]}],"arms":[{"label":"No-CM","type":"NO_INTERVENTION"},{"label":"CM-Maintenance","type":"EXPERIMENTAL"}],"summary":"This randomized, phase III trial was designed to test the efficacy of a low-dose chemotherapy-maintenance regimen, hypothesized to have anti-angiogenic activity, administered following standard chemotherapy in patients with early breast cancer whose tumors are hormone receptor negative.","primaryOutcome":{"measure":"Disease-free Survival","timeFrame":"5-year estimates, reported at a median follow-up of 6.9 years","effectByArm":[{"arm":"No-CM","deltaMin":74.7,"sd":null},{"arm":"CM-Maintenance","deltaMin":78.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.14"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["Australia","Belgium","Brazil","Chile","Hungary","Italy","Nigeria","Peru","Romania","South Africa","Switzerland"]},"refs":{"pmids":["27325862","27372069"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":["Elevated SGPT","Elevated SGOT","Leukopenia","Nausea","Vomiting"]}}